共 50 条
New recommendations in prostate cancer screening and treatment
被引:4
|作者:
Adams, Lisa K.
[1
,2
]
Ferrington, Lindsay S.
[3
]
机构:
[1] Feist Weiller Canc Ctr, Practices Hematol Oncol, Shreveport, LA 71103 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Recent Grad PA Program, Shreveport, LA 71105 USA
[3] Louisiana State Univ, PA Program, Shreveport, LA 71105 USA
来源:
关键词:
prostate cancer;
prostate-specific antigen;
Gleason score;
vaccine;
screening;
androgen deprivation therapy;
SKELETAL-RELATED EVENTS;
RISK;
MEN;
ANTIGEN;
STATISTICS;
GUIDELINES;
MANAGEMENT;
OUTCOMES;
D O I:
10.1097/01.JAA.0000451872.86566.bf
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Prostate cancer is the most commonly diagnosed nonskin cancer in men, with 233,000 new cases estimated for 2014. Nearly 30,000 deaths are predicted for 2014, second only to lung and bronchial cancer deaths. Early diagnosis is key to improving patient survival rates. Screening efforts have dramatically increased the detection rate, and now, 90% of new diagnoses are caught at the early stage of disease. However, new data are driving controversial changes to screening and treatment recommendations.
引用
收藏
页码:14 / 20
页数:7
相关论文